DORSET, UK – January 12, 2026 – TEK Optima Research has brought a custom AI datacentre in Dorset online and ramping up, marking a new phase for the company's DeepInsight platform. The Dorset facility, which until now has primarily served as the company's research and development base, will be the primary hub for running TEK Optima Research's proprietary AI models and processing imaging data from Cell Line Development (CLD) programmes for global partners.
Purpose-built infrastructure for biologics
The site combines ongoing R&D with a dedicated inference, compute, and storage environment designed around DeepInsight's high‑throughput analysis of microplate imaging data. Running on TEK Optima Research's own GPU‑powered infrastructure with Kubernetes‑based orchestration and S3‑compatible storage, the Dorset facility supports advanced label‑free cell counting, clone‑level growth tracking, and predictive growth modelling for monoclonal antibody CLD.
Processing workloads from global partners
The Dorset AI datacentre is already processing test and beta workloads from biologics and biomanufacturing partners around the world. By turning standard CLD imaging into decision‑ready analytics, DeepInsight helps teams select better monoclonal antibody clones earlier in development—reducing redundancy, shortening timelines, and de‑risking key choices that shape downstream manufacturing. This data‑driven approach is intended to support more efficient development of advanced biologic medicines, including anti‑cancer therapies, without requiring new hardware or disruptive changes to existing instrument workflows.
UK development and future expansion
Developed and operated in the UK, the Dorset facility also serves as the home for training and refining TEK Optima Research's custom machine learning models for CLD and beyond. As demand grows, the company plans to expand capacity at the site, building on its modular, custom‑designed compute and storage racks to support a broader range of cell types, workflows, and future applications of its cell fingerprinting technology.
About TEK Optima Research
TEK Optima Research develops AI-powered solutions for biopharmaceutical development, with the DeepInsight platform enabling faster, more accurate cell line selection for biologics manufacturing. Based in Dorset, UK, the company combines advanced machine learning with purpose-built infrastructure to help global partners accelerate the development of next-generation biologic therapies.
For more information, visit deepinsight.bio or contact brad@tekor.tech.
Media Contact
Brad Turner Founder and CEO TEK Optima Research Ltd Email: brad@tekor.tech Web: deepinsight.bio